127 related articles for article (PubMed ID: 15713893)
1. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.
Chen T; Pengetnze Y; Taylor CC
Mol Cancer Ther; 2005 Feb; 4(2):217-24. PubMed ID: 15713893
[TBL] [Abstract][Full Text] [Related]
2. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
3. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line.
Pengetnze Y; Steed M; Roby KF; Terranova PF; Taylor CC
Biochem Biophys Res Commun; 2003 Sep; 309(2):377-83. PubMed ID: 12951060
[TBL] [Abstract][Full Text] [Related]
4. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
5. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
8. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
9. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
10. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.
Abuharbeid S; Apel J; Zugmaier G; Knabbe C; Sander M; Gilbert S; Czubayko F; Aigner A
Naunyn Schmiedebergs Arch Pharmacol; 2005 Feb; 371(2):141-51. PubMed ID: 15700118
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines.
Golubovskaya VM; Gross S; Kaur AS; Wilson RI; Xu LH; Yang XH; Cance WG
Mol Cancer Res; 2003 Aug; 1(10):755-64. PubMed ID: 12939401
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
14. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous suppression of Src and signal transducer and activator of transcription 3 inhibits the growth of epithelial ovarian cancer cells.
Lee SW; Yoo J; Lee SH; Kim D; Kim YM; Kim YT
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(1):75-9. PubMed ID: 23427943
[TBL] [Abstract][Full Text] [Related]
16. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.
Wiener JR; Windham TC; Estrella VC; Parikh NU; Thall PF; Deavers MT; Bast RC; Mills GB; Gallick GE
Gynecol Oncol; 2003 Jan; 88(1):73-9. PubMed ID: 12504632
[TBL] [Abstract][Full Text] [Related]
17. Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis.
Delle Monache S; Sanità P; Calgani A; Schenone S; Botta L; Angelucci A
Exp Cell Res; 2014 Oct; 328(1):20-31. PubMed ID: 25128812
[TBL] [Abstract][Full Text] [Related]
18. Antrodia camphorata induces apoptosis and enhances the cytotoxic effect of paclitaxel in human ovarian cancer cells.
Liu FS; Yang PY; Hu DN; Huang YW; Chen MJ
Int J Gynecol Cancer; 2011 Oct; 21(7):1172-9. PubMed ID: 21897275
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells.
Griffin D; Wittmann S; Guo F; Nimmanapalli R; Bali P; Wang HG; Bhalla K
Gynecol Oncol; 2003 Apr; 89(1):37-47. PubMed ID: 12694652
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation.
Leung EL; Wong JC; Johlfs MG; Tsang BK; Fiscus RR
Mol Cancer Res; 2010 Apr; 8(4):578-91. PubMed ID: 20371672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]